Canadian Agency for Drugs and Technologies in Health. (2021). Pharmacoeconomic report: Indication : major depressive disorder in adults. Esketamine hydrochloride (Spravato) (Janssen inc.). Canadian Agency for Drugs and Technologies in Health.
Cita Chicago Style (17a ed.)Canadian Agency for Drugs and Technologies in Health. Pharmacoeconomic Report: Indication : Major Depressive Disorder in Adults. Esketamine Hydrochloride (Spravato) (Janssen Inc.). Ottawa: Canadian Agency for Drugs and Technologies in Health, 2021.
Cita MLA (9a ed.)Canadian Agency for Drugs and Technologies in Health. Pharmacoeconomic Report: Indication : Major Depressive Disorder in Adults. Esketamine Hydrochloride (Spravato) (Janssen Inc.). Canadian Agency for Drugs and Technologies in Health, 2021.
